Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pimozide
Drug ID BADD_D01774
Description A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Indications and Usage Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
Marketing Status approved
ATC Code N05AG02
DrugBank ID DB01100
KEGG ID D00560
MeSH ID D010868
PubChem ID 16362
TTD Drug ID D00KHM
NDC Product Code 66577-017; 76438-002; 49884-348; 49884-347; 14474-029
UNII 1HIZ4DL86F
Synonyms Pimozide | Antalon | Orap | Orap forte | R-6238 | R6238
Chemical Information
Molecular Formula C28H29F2N3O
CAS Registry Number 2062-78-4
SMILES C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Nervousness19.06.02.003---
Neuroleptic malignant syndrome08.05.01.005; 12.03.01.003; 15.05.04.015; 17.05.02.003---
Neuromyopathy15.05.03.010; 17.05.03.003---
Nocturia20.02.03.001---
Oculogyric crisis06.05.02.002; 17.01.03.002---
Opisthotonus17.01.03.005---
Orthostatic hypotension17.05.01.020; 24.06.03.004---
Palpitations02.11.04.012--
Pancytopenia01.03.03.003---
Parkinsonism17.01.05.003---
Periorbital oedema06.08.03.017; 10.01.05.010; 23.04.01.002--
Photophobia06.01.01.004; 17.17.02.006--
Pollakiuria20.02.02.007--
Posture abnormal15.03.05.029; 17.02.05.033---
Protrusion tongue07.14.02.002; 17.02.05.037---
Pruritus23.03.12.001--
Rash23.03.13.001---
Salivary hypersecretion07.06.01.009---
Schizophrenia19.03.04.001---
Sedation17.02.04.005---
Seizure17.12.03.001--
Shock24.06.02.002---
Skin disorder23.03.03.007---
Skin irritation23.03.04.009---
Somnolence17.02.04.006; 19.02.05.003--
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.027---
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene